Maltaq was approved by the FDA in July 2009 for the treatment of abnormal heart rhythms. Soon after entering the market, disturbing reports of liver failure were reported with the drug. More recently, the FDA has warned of association with severe, even life threatening, cardiovascular problems.
I encourage all my readers to discuss these new findings and associations with their doctors to minimize any risk that may present in their individual treatment plan.
About the Firm: The Michael Brady Lynch Firm is a trial firm with a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote and Topamax, as well as Actos Bladder Cancer and Fosamax Femur Fractures, and medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.
Recent Comments